ProMIS Neurosciences Inc. reports clinical-stage biotechnology developments around antibody therapeutics and vaccines that target toxic misfolded proteins in neurodegenerative diseases. Company news centers on PMN310, its lead humanized monoclonal antibody for Alzheimer’s disease, the PRECISE-AD clinical program, FDA Fast Track designation, biomarker research involving plasma pTau, and scientific publications or conference presentations tied to Alzheimer’s disease, ALS, and Parkinson’s disease.
Updates also cover operating and financial results, governance matters, shareholder votes, capital-structure actions, and investor conference participation. The company’s research disclosures emphasize its proprietary discovery platform and selective targeting of disease-specific toxic protein species rather than broader amyloid plaque binding.
ProMIS Neurosciences (PMN) entered a license agreement with Ossianix for TXP1 brain-delivery technology to pair with its Alzheimer’s antibody PMN310. The agreement includes options to apply TXP1 to PMN442 and PMN267, its Parkinson’s and ALS programs.
In Ossianix preclinical studies, TXP1 increased delivery of a therapeutic antibody to the brain by more than 65-fold. Ossianix will receive an upfront payment and is eligible for development, regulatory and commercial milestone payments, plus royalties on global net sales. ProMIS intends to fund short-term obligations with existing cash and expects its previously disclosed cash runway through 2027 to remain unchanged. Current PMN310 development is unaffected; advancement as intravenous and subcutaneous products remains subject to upcoming data.
ProMIS Neurosciences (PMN) reported third-quarter results and reaffirmed expected first-quarter 2027 unblinded topline data from its PRECISE-AD Alzheimer’s trial.
The Phase 1b readout will include 12-month safety, biomarker and cognitive outcomes. Patient visits are expected to finish in the fourth quarter of 2026. Previously reported pooled, blinded six-month results in 136 patients showed no ARIA-E, a type of brain swelling, and 4.4% ARIA-H, involving brain bleeding; all ARIA-H cases were mild and asymptomatic.
Quarterly net loss narrowed to $8.2 million from $11.6 million a year earlier. Cash reached $44.1 million at September 30, 2026, versus $6.1 million at year-end 2025. ProMIS expects cash to fund operations through 2027 and anticipates starting a registrational study toward the end of 2027, subject to FDA feedback. Development of a subcutaneous PMN310 formulation is underway.
ProMIS Neurosciences (Nasdaq: PMN) will participate in six healthcare and biotechnology conferences scheduled from November 9 through December 2, 2026. CEO Neil Warma will deliver presentations and fireside chats, and leadership will be available for one-on-one meetings. At CTAD, a poster will cover PRECISE-AD interim safety and biomarker data previously presented on July 28, 2026.
ProMIS Neurosciences (Nasdaq: PMN) will report third-quarter 2026 financial results and provide corporate updates on November 12, 2026. The results cover the quarter ended September 30, 2026. A conference call and webcast will begin at 4:30 p.m. Eastern Time that day, with a webcast replay available afterward in the Investors section of the company website.
ProMIS has also published an investor Q&A, PMN310 Scientific and Clinical Update (November 2026), outlining the scientific rationale distinguishing PMN310 from other amyloid-targeting approaches.
ProMIS Neurosciences (PMN) appointed Ivana Rubino as Chief Commercial Officer, effective October 5, 2026, to lead commercial preparation for PMN310.
Rubino previously held senior roles at Biogen and Roche, with experience in Alzheimer’s development, medical strategy and launch readiness. Her responsibilities include market access and payer planning, patient and physician pathways, launch readiness and lifecycle strategy. She will work with the Chief Medical Officer on pivotal development strategy and evidence generation, and contribute to regulatory strategy and business development. ProMIS expects 12-month PRECISE-AD topline data in Q1 2027.
In connection with the appointment, ProMIS granted Rubino an option to purchase 80,000 common shares at $9.37 per share, effective October 5, 2026. The option has a 10-year term.
ProMIS Neurosciences (Nasdaq: PMN) will participate in several healthcare and investor conferences in September 2026 in New York, including events hosted by Cantor, Moody Capital, H.C. Wainwright and Roth, plus a World Alzheimer’s Day appearance at the Nasdaq Tower on September 21.
Company executives Neil Warma (President & CEO), Dr. Larry Altstiel (CMO) and Carie Pierce (VP, Investor Relations & External Affairs) will discuss the EpiSelect™ platform, ProMIS’ approach to targeting toxic misfolded proteins in neurodegenerative diseases, and PMN310, its lead asset in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease. ProMIS recently reported blinded 6‑month interim data from this fully enrolled trial, with 12‑month topline data expected in early 2027. Webcast links and replays will be available via the Investors section of the company’s website.
ProMIS Neurosciences (Nasdaq: PMN) reported second quarter 2026 results and a corporate update, highlighted by positive blinded six‑month interim data from PRECISE-AD, its Phase 1b trial of Alzheimer’s candidate PMN310. Among 136 safety‑evaluable patients across all APOE genotypes, there were no ARIA-E cases and a 4.4% rate of mild, asymptomatic ARIA-H, with no treatment-related serious adverse events or drug-related discontinuations.
In the blinded pooled biomarker analysis, plasma pTau217 declined about 15% and CSF MTBR-tau243 about 13.3% from baseline. Cash and short-term investments were $53.4 million at June 30, 2026, up from $6.1 million at year-end 2025, mainly from $70.1 million in January private placement proceeds, funding operations through 2027. Q2 2026 net loss was $11.7 million ($1.28/share) versus $10.1 million ($7.26/share) a year earlier, as R&D and G&A spending increased with pipeline progression.
ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company focused on antibody therapeutics and vaccines for neurodegenerative diseases, will report its second quarter 2026 financial results and provide a business update on August 13, 2026.
The company will host an investor conference call and webcast on August 13, 2026 at 4:30 p.m. Eastern Time. U.S. investors can dial 1-877-407-9208, international participants can dial 1-201-493-6784, using conference ID 13761812. A replay will be available in the Investors section of the ProMIS website.
ProMIS Neurosciences (Nasdaq: PMN) reported positive blinded six‑month interim safety and biomarker data from PRECISE-AD, its Phase 1b trial of PMN310 in 136 Alzheimer’s patients. PMN310 showed a favorable safety profile across all genotypes, with no ARIA-E, 4.4% total ARIA consisting only of mild, asymptomatic ARIA-H, no treatment-related serious adverse events, and no drug-related discontinuations as of the cutoff.
On a blinded basis, 68.5% of patients had declines in plasma pTau217 and 62.5% had declines in CSF MTBR-tau243 versus expected natural-history increases, changes the company links to possible target engagement and the 3:1 randomization, while cautioning these biomarker trends do not establish efficacy. The study has enrolled 144 participants on 5, 10, and 20 mg/kg IV doses for 12 months, with unblinded 12‑month topline results, including efficacy data, expected in Q1 2027.
ProMIS Neurosciences (Nasdaq: PMN) will host a webinar on July 28, 2026, 8:00–9:00 am ET to review upcoming six-month blinded interim data from the PRECISE-AD Phase 1b trial of its lead Alzheimer’s candidate PMN310. Company executives and KOLs Dr. Will Mantyh and Dr. Michael Weiner will discuss aggregate safety findings and trends in select biomarkers in patients with early Alzheimer’s disease.
PRECISE-AD is a randomized, double-blind, placebo-controlled study of multiple ascending intravenous doses (5, 10, 20 mg/kg) of PMN310 over twelve months in 144 enrolled participants. PMN310, a selective anti-amyloid-beta oligomer antibody, received FDA Fast Track designation in July 2025.